Recent patents on anti-infective drug discovery
-
Recent Pat Antiinfect Drug Discov · Sep 2020
Transmissibility and Epidemicity of COVID-19 in India: A Case Study.
The global outbreak of COVID-19 incepted in Wuhan, China in the late 2019. It is still unclear about the origin of the infection. Over time, it has migrated geographically to 150 countries in the world and World Health Organization (WHO) has declared the infectious disease to be pandemic. ⋯ The transmissibility of COVID-19 and its epidemicity in India is discussed. In specific, a case study on COVID -19 cases in the state of Kerala relating the transmissibility is also summarized. Further, data related to patents on corona virus is also discussed. From the analysis, it can be concluded that there is a possibility of COVID-19 transmission even during incubation period. The preventive measures to overcome COVID-19 and methods to increase the immunity are discussed.
-
Recent Pat Antiinfect Drug Discov · Jan 2020
ReviewThe Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
To date, severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) has infected millions of individuals worldwide. This virus causes coronavirus disease 2019 (COVID-19) and has led to numerous deaths worldwide. A large percentage of infected patients present asymptomatically, augmenting the spread of the virus. ⋯ Outcomes and biomarkers of patients treated with TCZ are compared to patients treated with standard of care regimens. Interleukin-6 (IL-6), a prominent inflammatory cytokine involved in CRS in various inflammatory conditions, may have a vital role in the underlying mechanism involved in debilitating SARS-CoV-2 infections and could serve as a viable treatment target. Studies suggest that TCZ may aid in the recovery of patients with COVID-19 and reduce mortality.
-
Recent Pat Antiinfect Drug Discov · Jan 2018
Screening and Potential of the Incidence of Resistance Transfer Among the Multidrug and Heavy Metal Resistant Gram-Negative Isolates from Hospital Effluents of Northern India.
Hospital wastewater has a high amount of both organic and inorganic matter, as well as high densities of living organisms, including pathogenic, and environmental bacteria. It has been suggested that genes encoding resistance to an antibiotic can be located together with heavy metals resistance genes on either the same genetic structure (plasmid) or different genetic structures within the same bacterial strain. Resistance transfer is mainly attributed to conjugation since many antimicrobial resistance genes are situated on mobile elements, such as plasmids and conjugative transposons, whereas renovation and transduction are usually more limited. Our study confirmed the flow of resistance genes between indigenous and foreign organisms and indicated the possibility of resistance transfer from environmental reservoirs to pathogenic strains, which should be underlined in the future. The recent patents on drug resistance (US20030130169, WO/2001/060387, WO/2016/151092) and gene transfer (JP2003189855, JP2010094090), helped in this study. ⋯ We can recommend that the hospital water is heavily polluted with several types of antibiotics, toxic metals as well as the potentially hazardous bacterial flora because of their capacity to resist one or the other well known antibiotic and chemotherapeutic agents. These studies provide evidence that a wide variety of clinically important antibiotic and metal resistance genes is mobile within aquatic bacterial communities one step ahead of the above, we can envisage the alarming situation prevailing in our system and surrounding in the light of transmissible nature of R-plasmids.
-
Recent Pat Antiinfect Drug Discov · Jan 2018
ReviewIbalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
Heavily treated HIV-1 infected patients may have limited therapeutic alternatives. In order to ensure sustained HIV-RNA suppression in these patients and to improve current antiretroviral treatment regimens in the fight against multi-drug resistant strains, new drugs are needed. Recently, two new drugs among the new generation of entry inhibitors showed promises for both their characteristics and mechanism of action. ⋯ The history of ibalizumab and fostemsavir will be written in next years. Continuing the research will be crucial to obtain evidence based guidelines for the management of heavily treated HIV-1 infected patients with limited therapeutic options.
-
Recent Pat Antiinfect Drug Discov · Jan 2016
ReviewTargets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
The American trypanosomiasis, Chagas disease, is a parasitic infection typically spread by triatomine vectors affecting millions of people all over Latin America. Existing chemotherapy is centered on the nitroaromatic compounds benznidazole and nifurtimox that provide unsatisfactory results and substantial side effects. So, the finding and exploration of novel ways to challenge this neglected disease is a main priority. ⋯ In summary, loans on anti-Chagas disease agents focused to specific parasite targets as their metabolic pathways or specific enzymes will be summarized. Targets will also be specifically discussed. Patent literature collected and published from 2000 to 2015, alleging inhibitors for specific T. cruzi targets or trypanocidal activity was achieved over the search database from Delphion Research intellectual property network including international patents and the European patent office, Espacenet.